Med. praxi. 2011;8(12):518-523 [Interní Med. 2008; 10(1): 26-30]

Do we use antimicrobial therapy?

doc.MUDr.Václav Dostál, CSc.
Oblastní nemocnice Jičín, LDN Nový Bydžov

Worldwide situation forces experts to muse above decreasing of the antimicrobial therapy effectivness. The growing antibiotics resistance

is becomig a global medical problem. Rational use of antibiotics is necessary presumption to preserve effective antibacterial therapy

for future generations. A significant achievements have been reached in the consensus about international co-operation. Inadequate

recommended of the antimicrobial therapy along carries the hazard of the microbial resistance, drugs toxicity, undesirable interactions

and other therapy complications. Necessary steps to slow down the progress of antibiotics resistance are known, however no always

respected and achieved. Qualified teams of infectious disease specialists, microbiologists, biochemists, and pharmacists are needed to

ensure prudent indications of antibiotics in cases of proved or highly suspected bacterial infections as well as adequate informations

about the principles of the antibiotics therapy in the general public. The need of the new antibiotics is necessary, however their placement

to the common practice must be prudent. Their using can be recommended in choice situations only.

Keywords: antibiotic resistance, rational antibiotic prescription, education, strategy

Published: December 15, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dostál V. Do we use antimicrobial therapy? Med. praxi. 2011;8(12):518-523.
Download citation

References

  1. Tunger O, et al. Rational antibiotic use. J Infect Developing Countries 2009; 3: 88-93. Go to original source... Go to PubMed...
  2. Vashishtha VMV. Growing Antibiotics Resistance and the Need for New Antibiotics. Indian Pediatrics 2010; 47: 505-506. Go to original source... Go to PubMed...
  3. Rittenhouse S, et al. Selection of Retapamulin, a Novel Pleuromutilin for Topical Use. Antimicrob Agents Chemother 2006; 50: 3882-3885. Go to original source... Go to PubMed...
  4. Sykes RB, Matthew M. The ?-lactamases of Gram-negative bacteria and their role in resistance to ?-lactam antibiotics. J Antimicrob Chemother 1976; 2: 115-157. Go to original source... Go to PubMed...
  5. Dostál V. Horečnatý stav. In Beneš J. Infekční lékařství. Galén 2009: 381-398.
  6. Dostál V. Racionální antibiotická terapie. In Dostál V, a kol. Infektologie. Karolinum Praha 2004: 47-62.
  7. Tillotson GS. Antibiotic development: a victim of market forces? IDrugs 2008; 11: 340-346. Go to PubMed...
  8. Dostál V, Štěrbová L. Rozpaky nad antibiotickou terapií u starší populace Kazuistika. Český kongres o infekčních nemocech, Mikulov 9.-11. 11. 2011. Programový sborník, s. 32.
  9. Quek CL. A retrospective study evaluating the use of imipenem & meropenem in a tertiary referral hospital in Singapore. SGH 16th Annual Scientific Meeting; 2007: 27-28.
  10. Buke C, et al. Irrational use of antibiotics among university students. J Infect 2005; 51: 135-139. Go to original source... Go to PubMed...
  11. ZN. Lékárníci proti ATB rezistenci. ZN 2011; 60: 2.
  12. Shaban L, et al. Prevalence and antimicrobial resistance pattern of bacterial meningitis in Egypt. Ann Clin Microbiol Antimicrob 2009; 8: 26. Go to original source... Go to PubMed...
  13. Borg MA. Antibiotic resistance surveillance and control in the Mediterranean region: report of the ARMed Consensus Konference. J Infect Dev Ctries 2009; 3: 654-659. Go to original source... Go to PubMed...
  14. Amabile-Cuevas CF. Antibiotic resistance in Mexico: a brief overview of the current status and its cause. J Infect Dev Ctries 2010; 4: 126-131. Go to original source... Go to PubMed...
  15. Boucher HW. Challenges in Anti-Infective Development in the Era of Bad Bugs, No Drugs: A Regulatory Perspektive Using the Example of Bloodstream Infection as an Indication. Clin Infect Dis 2010; 50: S4-9. Go to original source... Go to PubMed...
  16. Dostál V. Diagnostika infekčních nemocí. http://www.eclk.cz.
  17. Jensen JU, et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med 2011; 39: 2048-2058. Go to original source... Go to PubMed...
  18. Chow A, Robinson JL. Fever of unknown origin in children: a systematic review. World J Pediatr. 2011; 7: 5-10. Go to original source... Go to PubMed...
  19. Bleeker-Rovers CP, van der Meer JW, Oyen WJ. Fever of unknown origin. Semin Nucl Med. 2009; 39: 81-87. Go to original source... Go to PubMed...
  20. Dostál V. Léčíme antibiotiky racionálně? Medicína po promoci. 2011; 12: 69-75.
  21. Kohanski MA, Dwyer DJ, and Collins JJ. How antibiotics kill bacteria: from targets to network. Nat Rev Microbiol. 2010; 8: 423-435. Go to original source... Go to PubMed...
  22. Wright JA, Nair SP. Interaction of staphylococci with bone. Int J Med Microbiol. 2010; 300: 193-204. Go to original source... Go to PubMed...
  23. http://www.who.int/mediacentre/factsheets/fs194/en/.
  24. http://czpres.mzcr.cz/Categories/483-Konference.html.
  25. http://www.abs-international.eu.
  26. http://ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/Pages/index.aspx.
  27. http://www.tribune.cz/clanek/16873.
  28. Nathwani D. Tigecycline: clinical evidence and formulary positioning. Int J Antimicrob Agents 2005; 25: 185-192. Go to original source... Go to PubMed...
  29. Esposito S, Leone S. Antimicrobial treatment for Intensive Care Unit (ICU) infections including the role of the infectious disease specialist. Int J Antimicrob Agents 2007; 29: 494-500. Go to original source... Go to PubMed...
  30. Bal AM, Gould IM. Empirical antimicrobial treatment for chemotherapy-induced febrile neutropenia. Int J Antimicrob Agents 2007; 29: 501-509. Go to original source... Go to PubMed...
  31. Meka VG, Pillai SK, Sakoulas G, et al. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J Infect Dis 2004; 190: 311-317. Go to original source... Go to PubMed...
  32. Butler MS and Cooper MA. Antibiotics in the pipeline in 2011. J Antibiotics 2011; 64: 413-425. Go to original source... Go to PubMed...
  33. SrinivasanA. Three Steps to Antibiotic Stewardship 11/15/2010, www.medscape.com/viewarticle/731784.
  34. Dellit TH. Antimicrobial Stewardship Guidelines. Clin Infect Dis 2007; 44: 159-177. Go to original source... Go to PubMed...
  35. Hitt E. ID Society Calls for 10 New Antimicrobials by 2020, Medscape Medical News, March 18, 2010.
  36. Infectious Diseases Society of America. Clin Infect Dis. 2010 Apr 15; 50(8): 1081-1083. The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020.
  37. Nation RL, Li J. Colistin in the 21st Century. Curr Opin Infect Dis. 2009; 22: 535-543. Go to original source... Go to PubMed...
  38. www.cls.cz./Léčebné standardy/Další odborné projekty.
  39. Dlouhý P, Honegr K, Krbková L, Pícha D, Roháčová H, Štruncová V. Lymeská borrelióza: Doporučený postup v diagnostice, léčbě a prevenci. www.infekce.cz/.
  40. www.infekce.cz Terapie chlamydiových infekcí. Konsenzus primářů infekčních pracovišť k problému terapie chlamydiových infekcí. Setkání přednostů a primářů infekčních oddělení v Černém Dole, 30. 4. 2010.




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.